Momenta Pharmaceuticals, Inc. (MNTA)

[tony111]

Humira and Copaxone are not making money. Copaxone 40 is making very little money since MyL cut price to the bone. Humira not going to be on the market till 2023. Their novel drug pipeline is great but no proof of concept yet (not even phase 1 efficacy data).

2.2B market cap is baking in the company will have revenue of ~300M a year within 3 years.

I am guessing there is a buyout MNTA or its biosimilar business in talk causing the surge.

In the past MNTA raised capital in 19, 15, 14 and low teens range. If they dun plan to sell the company, raising cash at 30 is a very good deal.